Provided by Tiger Fintech (Singapore) Pte. Ltd.

Candel Therapeutics, Inc.

4.51
-0.0600-1.31%
Post-market: 4.540.0300+0.67%19:45 EDT
Volume:385.55K
Turnover:1.75M
Market Cap:213.03M
PE:-2.59
High:4.81
Open:4.48
Low:4.41
Close:4.57
Loading ...

Company Profile

Company Name:
Candel Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2003
Employees:
38
Office Location:
117 Kendrick Street,Suite 450,Needham,Massachusetts,United States
Zip Code:
02494
Fax:
- -
Introduction:
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Directors

Name
Position
Paul Peter Tak
Director,President and Chief Executive Officer
Paul B. Manning
Director,chairman of the board
Chris Martell
Director
Diem Nguyen
Director
Edward J. Benz, Jr.
Director
Estuardo Aguilar Cordova
Director
Gary J. Nabel
Director
Joseph C. Papa
Director
Renee Gaeta
Director

Shareholders

Name
Position
Paul Peter Tak
Director,President and Chief Executive Officer
Jason A. Amello
Chief Financial Officer, Treasurer and Secretary
Francesca Barone
Chief Scientific Officer
Seshu Tyagarajan
Chief Technical and Development Officer
W. Garrett Nichols
Chief Medical Officer